Bronte Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $111M | Buy |
187,870
+33,177
| +21% | +$19.6M | 8.73% | 4 |
|
|
2025
Q1 | $115M | Buy |
154,693
+1,910
| +1% | +$1.42M | 9.33% | 3 |
|
|
2024
Q4 | $128M | Buy |
152,783
+15,741
| +11% | +$13.2M | 10.09% | 2 |
|
|
2024
Q3 | $144M | Sell |
137,042
-2,412
| -2% | -$2.54M | 11.71% | 3 |
|
|
2024
Q2 | $147M | Sell |
139,454
-5,619
| -4% | -$5.91M | 11.47% | 2 |
|
|
2024
Q1 | $140M | Sell |
145,073
-348
| -0.2% | -$335K | 11.4% | 3 |
|
|
2023
Q4 | $128M | Buy |
145,421
+3,979
| +3% | +$3.49M | 11.41% | 3 |
|
|
2023
Q3 | $116M | Buy |
141,442
+3,126
| +2% | +$2.57M | 11.72% | 3 |
|
|
2023
Q2 | $99.4M | Buy |
138,316
+1,943
| +1% | +$1.4M | 9.59% | 3 |
|
|
2023
Q1 | $112M | Sell |
136,373
-6,350
| -4% | -$5.22M | 13% | 2 |
|
|
2022
Q4 | $103M | Sell |
142,723
-4,452
| -3% | -$3.21M | 12.99% | 2 |
|
|
2022
Q3 | $101M | Sell |
147,175
-2,014
| -1% | -$1.39M | 12.63% | 3 |
|
|
2022
Q2 | $88.2M | Buy |
149,189
+10,172
| +7% | +$6.01M | 10.11% | 3 |
|
|
2022
Q1 | $97.1M | Buy |
139,017
+8,557
| +7% | +$5.98M | 8.16% | 2 |
|
|
2021
Q4 | $82.4M | Buy |
130,460
+6,236
| +5% | +$3.94M | 5.43% | 4 |
|
|
2021
Q3 | $75.2M | Buy |
124,224
+6,755
| +6% | +$4.09M | 5.5% | 4 |
|
|
2021
Q2 | $65.6M | Buy |
117,469
+58,082
| +98% | +$32.4M | 4.68% | 4 |
|
|
2021
Q1 | $28.1M | Buy |
59,387
+40,334
| +212% | +$19.1M | 3.19% | 7 |
|
|
2020
Q4 | $9.21M | Buy |
+19,053
| New | +$9.21M | 1.45% | 11 |
|